
Roche's Columvi expansion bid in danger as FDA's Martin Makary, Richard Pazdur push for more US enrollment in cancer ...
Roche looks unlikely to be able to move its DLBCL drug Columvi earlier in the treatment sequence after experts in an FDA advisory committee joined the agency in questioning the regional imbalance of clinical trial data. What’s more, both FDA Commissioner …